Drugs / Vorbipiprant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05205330 | Nov 2021 → Dec 2026 expected | colorectal cancer, gastric cancer | Rottapharm Biotech | Active not recruiting | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT05845450 | May 2023 → May 2027 expected | colorectal carcinoma | Gruppo Oncologico del Nord-Ovest | Recruiting | No outcome recorded |
| Phase 2 | NCT03163966 | Oct 2017 → Jan 2019 | — | Rottapharm Biotech | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | Rottapharm Biotech | Results Phase I/II study of vorbipiprant combined with anti-PD-1 immunotherapy results in metastatic gastrointestinal non-colorectal cancers presented at ASCO 2025 rottapharmbiotech.com ↗
Vorbipiprant combined with PD-1 blockade was well tolerated and showed signs of activity in non-colorectal GI cancers, thus confirming a broader spectrum of activity, on top of the results obtained in MSS mCRC. |
| 2024-12-02 | Rottapharm Biotech | Results Vorbipiprant combined with PD-1 blockade for refractory microsatellite stable metastatic colorectal cancer phase I/II trial results published in Clinical Cancer Research rottapharmbiotech.com ↗
The combination achieved a disease control rate (DCR) of 50% across the entire cohort, and a notable DCR of 25% in the subgroup of patients with liver metastases, that are usually refractory to immunotherapy approaches. |
| 2024-05-31 | Rottapharm Biotech | Results Updated results and subgroup analysis of the phase I/II study of CR6086 (vorbipiprant) and balstilimab in advanced colorectal cancer presented at ASCO 2024 rottapharmbiotech.com ↗
The analysis indicates that vorbipiprant combined with an anti-PD-1 showed promising efficacy also in patients with liver metastases |
| 2023-10-23 | Rottapharm Biotech | Results Rottapharm Biotech discloses at ESMO 2023 favourable results from the Phase 1/2 study of the EP4 receptor antagonist CR6086 combined with the anti-PD-1 balstilimab in advanced colorectal cancer rottapharmbiotech.com ↗
Rottapharm Biotech announces favourable clinical results of CR6086, its potent and selective small molecule antagonist of the prostaglandin EP4 receptor, combined with the anti PD-1 antibody balstilimab (Agenus Inc, Nasdaq: AGEN) in advanced colorectal cancer (CRC). |
All press releases naming this drug 5 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vorbipiprant | “CR6086 (Vorbipiprant) is a potent and selective, orally bioavailable, targeted immunomodulator small molecule acting as an EP4 receptor antagonist.” NCT05205330 ↗ |
| Known as | CR6086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205330 ↗ |
| Known as | CR6086 SODIUM SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067994 ↗ |
| Known as | VORBIPIPRANT SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067994 ↗ |
| Action | Inhibit | “Prostanoid EP4 receptor antagonist” CHEMBL6067994 ↗1“EP4 receptor antagonist” NCT03163966 ↗ |
| Modality | Small molecule | “small molecule prostaglandin EP4 receptor antagonist” NCT03163966 ↗ |
| Route | Oral | “oral CR6086 capsules” NCT03163966 ↗ |
| Target | PTGER4 | “Prostanoid EP4 receptor antagonist” CHEMBL6067994 ↗ |